Lupin completes acquisition of two brands from Sanofi in Europe and Canada
The transaction aligns with Lupin's strategy to grow its global presence in Specialty areas
The transaction aligns with Lupin's strategy to grow its global presence in Specialty areas
Open a printable version of this pageEmail the URL of this page to a friend
The drug will be manufactured at the group’s formulation manufacturing facility at Ahmedabad SEZ II, India
The first and only oral androgen deprivation therapy treatment for men with advanced prostate cancer
This agreement paves the way for the introduction of YESAFILI into the Canadian market
Sirius JV will be owned 51% by Sirius and 49% by Adani
The brands Aarne in Germany and Nalcrom in Canada and the Netherlands are being acquired
The transfer of the distribution rights will strengthen Sandoz's immunology and biosimilar portfolio
The CAPSUL solution enables optimal process performance for production of premier quality PCL grades at competitive rates
Subscribe To Our Newsletter & Stay Updated